NuvOx Pharma has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
Search
Recent Posts
See AllTucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO
Tucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics wi